Skip to main content
. Author manuscript; available in PMC: 2024 Jun 7.
Published in final edited form as: J Thorac Oncol. 2020 Dec 31;16(4):583–600. doi: 10.1016/j.jtho.2020.12.010

Figure 6.

Figure 6.

Anti-CD73 therapy-induced tumor reduction in EGFR-mutant murine lung cancers. (A) NT5E (CD73) and ADORA1 RNA expression levels in EGFR-mutant tumors and normal lung. (B) adenosine and AMP metabolite levels in EGFR-mutant tumors and normal lung. (C) CD73 immunohistochemistry for EGFR-mutant tumors and adjacent normal lung. (D) The change of tumor sizes with 2 weeks of treatment was documented and compared between vehicle-treated and anti-CD73 treated groups.